+Compare
ALLK
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
708.89M

ALLK Price Prediction, Allakos AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
ALLK Trading results, last 6 months
AI Robots NameP/L
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EST Dec 05, 2022

ALLK's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ALLK turned positive on November 08, 2022. Looking at past instances where ALLK's MACD turned positive, the stock continued to rise in 38 of 44 cases over the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 07, 2022. You may want to consider a long position or call options on ALLK as a result. In of 68 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLK advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 153 cases where ALLK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ALLK moved out of overbought territory on December 05, 2022. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALLK broke above its upper Bollinger Band on November 29, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.015) is normal, around the industry mean (25.700). P/E Ratio (0.000) is within average values for comparable stocks, (74.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.828). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (313.544).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALLK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

ALLK is expected to report earnings to -52 cents per share on February 28

Allakos ALLK Stock Earnings Reports
Q4'22
Est.
$-0.53
Q3'22
Beat
by $0.22
Q2'22
Missed
by $0.13
Q1'22
Missed
by $1.65
Q4'21
Missed
by $0.42
The last earnings report on November 07 showed earnings per share of -52 cents, beating the estimate of -75 cents. With 606.92K shares outstanding, the current market capitalization sits at 708.89M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (NASDAQ:SRNE).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.92B. The market cap for tickers in the group ranges from 160 to 287.41B. NONOF holds the highest valuation in this group at 287.41B. The lowest valued company is CDXI at 160.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 171%. PVCT experienced the highest price growth at 141%, while AGLE experienced the biggest fall at -63%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -3%. For the same stocks of the Industry, the average monthly volume growth was -42% and the average quarterly volume growth was -85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 60
SMR Rating: 92
Profit Risk Rating: 94
Seasonality Score: 23 (-100 ... +100)
AI
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I. Advisor
published General Information

General Information

a provider of antibody therapeutics for allergic and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
975 Island Drive
Phone
+1 650 597-5002
Employees
192
Web
https://www.allakos.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SHISX67.02-0.76
-1.12%
BlackRock Health Sciences Opps Svc
DCURX11.49-0.21
-1.79%
DWS CROCI US R6
JIVAX28.68-0.53
-1.81%
JPMorgan U.S. Applied Data Sci Val A
SLYCX14.34-0.28
-1.92%
SEI Large Cap Y (SIMT)
LFGQX19.34-0.47
-2.37%
Lord Abbett Focused Growth R3

ALLK and

Correlation & Price change

A.I.dvisor tells us that ALLK and ACAD have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALLK and ACAD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLK
1D Price
Change %
ALLK100%
-2.16%
ACAD - ALLK
33%
Poorly correlated
-3.30%
ARCT - ALLK
26%
Poorly correlated
-7.49%
SRRK - ALLK
25%
Poorly correlated
-2.54%
SPRB - ALLK
25%
Poorly correlated
+1.74%
OCGN - ALLK
23%
Poorly correlated
-6.83%
More